42 research outputs found
Changes in epinephrine dispensings and allergy hospitalisations in Sweden in the years following the removal of autoinjector co-payments [Elektronisk resurs]
No full textIntroduction: To understand any possible healthcare system benefits and changes of behavior for the patients with the change in prescription co-payment in Sweden we aimed to provide an update on the trends of EAI dispensings and hospitalizations for the Swedish paediatric population (ages 0-19 years), from 2018 to 2022, including by sex and geographic region. Methods: Using publically-available, population-level aggregate data from Sweden's National Board of Health and Welfare, we extracted information on annual epinephrine (ATC C01CA24) dispensings per 1,000 inhabitants from 2018 to 2023, overall, as well as stratified by sex, age groups and geographic region; and on inpatient stays 2018-2022 (ICD-10 code T78), anaphylaxis and other allergic reactions, per 100,000 individuals. We compared these estimates to those for adults ages 18 + years, for whom prescription co-payments remained in place. Results: EAI dispensings remained stable for children and adults across the study period, with the exception of statistically significant decreases amongst dispensings for children across all ages in 2021 (6.65/1,000) and 2022 (7.37/1,000), compared to 2018 (8.63/1,000) (each year p = 0.03 compared to 2018 dispensings). National EAI dispensings did not statistically significantly differ from 2018 (8.63/1,000) to 2023 (6.70/1,000) amongst children. EAI dispensings for children ages 5 + years consistently exceed dispensings for adults per 1,000 inhabitants; only children aged 0-4 years had proportionately fewer dispensings. Children ages 0-4 years tended to be hospitalised more often than older children, albeit these differences were not statistically significant (all p &gt; 0.97). Conclusion: Subsequent to the removal of out-of-pocket costs for EAI, dispensings did not increase for children, although more EAI were dispensed to children from age 5 years, compared to younger children. Allergy-related hospitalisations were highest amongst children ages 0-4, lower amongst children ages 5-14 years, and again higher amongst those ages 15-19 years.</p
Paediatric hospitalizations due to allergic reactions increasing in Finland and decreasing in Sweden
No full textNon peer reviewe
Trends in severe allergic reactions of adults in Finland between 1999 and 2020: A national population study
No full textNon peer reviewe
Current Care Guidelines had no immediate effects on antitussive prescriptions to Finnish children
No full textNormative data for the Impairment Measure for Parental Food Allergy–Associated Anxiety and Coping Tool
No full textNon-Atopic Asthma And Atopic Asthma Are Associated With Reduced Pulmonary Function By Age 7 Years
No full textPrimary prevention of food allergy: beyond early introduction
No full textAbstract Food allergy typically begins early in life and persists as a lifelong condition. Delayed introduction of allergenic foods followed by years of hesitancy to introduce these foods early may have contributed to the increase in food allergy prevalence in recent decades. Most infant feeding guidelines focus on the importance of early introduction of allergenic foods in infants at around age 4–6 months. However, regular, ongoing ingestion of allergenic foods is also critical for the primary prevention of food allergy. Similarly, intermittent exposure to cow’s milk formula (CMF) in early infancy increases the risk of cow’s milk allergy (CMA), while regular exposure (if it is introduced) prevents it. Families hesitant to introduce allergenic foods to their infant at home (despite education) should be offered introduction in a primary care clinic. Infants who have failed primary prevention should be referred to an allergist for consideration of early infant oral immunotherapy (OIT)
Generic Health-Related Quality of Life of Children With Severe Peanut or Tree Nut Allergy
No full textAim Food allergies may decrease health-related quality of life. We assessed health-related quality of life in Finnish children at risk of a severe peanut or tree nut allergy and their parents. Methods Study included children aged 3-15 years referred to Tampere University Hospital for suspected severe nut allergy. Eligibility criteria included a history of anaphylaxis and/or molecular immunology testing referring for severe peanut and/or tree nut allergy. Health-related quality of life was assessed with generic questionnaires 15D for adults, 16D for teenagers or 17D for children, with scores compared with age group-matched population references. Results A total of 101 children (mean age 7.7 +/- 2.9 years) and parent pairs were enrolled. The mean 16D score for 11 teenagers aged 12-15 years and mean 15D score for 101 parents was similar to reference populations; parental distress was borderline statistically worse (0.890 vs. 0.932, p = 0.013). The mean 17D score for 90 children aged 3-11 years was significantly higher (0.959 vs. 0.938) than in references (p < 0.01). Conclusion Children with a suspected severe peanut or tree nut allergy had a comparable health-related quality of life to the reference population. Distress among their parents seemed to be increased, warranting more focus on parental counselling.Peer reviewe
